As I see it

Share this article:
While some in the pharmaceutical industry think there is altogether too much public focus on drug risks at the expense of drug benefits, it may be argued that, if true, that is a consequence of the way the post-marketing drug experience is set up. It's biased in favor of reporting adverse events, and has no incentives for reporting benefits.

That may be about to change. A novel reporting system, currently being tested in Arizona by the Critical Path Institute (CPI) with FDA encouragement, is using poison-center pharmacists to interview patients taking two pulmonary drugs at 55 supermarket pharmacies.

According to FDA director of drug safety Gerald J. Dal Pan, initial results appear to bridge a gap in the 300,000 annual spontaneous reports from the FDA's MedWatch program—95% of which come from drug company networks— by providing a denominator. Dal Pan says the FDA faces “quite a challenge” from the three-fold increase in MedWatch reports that has outpaced a 50% increase in scripts from 1994 to 2004.

CPI president and FDA adviser Raymond L. Woosley describes the program as one facet of his institute's activities, many of which could benefit product developers by “facilitating change on neutral ground.” For example, he said, CPI has found data showing that 65% of patients prescribed warfarin had gene variants affecting their responses. Genetically determined dosages may be achieved by using Roche's AmpliChip technology.

The pilot's methodology has enormous implications for the future if it is expanded under the new Medicare Part D requirement that pharmacies conduct Maintenance Therapy Management for Medicare drug patients.

The response in Arizona pharmacies has been so strong that CPI plans to expand the initiative to cover SSRIs and introduce it to other drug chains.

Dickinson is editor of Dickinson's FDA Webview (

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications